Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregg Stone

Cardiovascular Disease New York, NY Medical Doctor

NPI 1134206956 CMS profile 50779

161 Fort Washington Ave, New York, NY 10032

Open in the dashboard

General payments

$1,991,902

305 records reported · program years 2019–2025

Research payments

$442,584

Paid to them · 30 records reported · program years 2019–2025

Ownership & investment interest

$3,980,173

3 holdings reported · through program year 2025

Research they led as principal investigator

$245,050 paid to institutions, not to them · program years 2021–2024

Through program year 2025, Gregg Stone of New York, NY is reported in the CMS Open Payments database as having received $1,991,902 across 305 general payments and $442,584 in research payments paid to them. Separately, studies naming them as principal investigator received $245,050 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $3,980,173 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $263,680 24
2025 Research $135,000 6
2024 General $195,664 44
2024 Research $90,084 6
2023 General $298,389 50
2023 Research $90,000 6
2022 General $427,151 70
2022 Research $90,000 7
2021 General $238,125 37
2021 Research $37,500 5
2020 General $234,106 23
2019 General $334,788 57
2025 Ownership $1,467,539 1
2024 Ownership $1,467,539 1
2023 Ownership $1,045,095 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregg Stone
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Gregg Stone were reported at $263,680. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Gregg Stone Cardiovascular Disease median Middle half National median
2019 $334,788 $450 $127–$1,392 $163
2020 $234,106 $242 $77–$751 $114
2021 $238,125 $335 $101–$1,037 $132
2022 $427,151 $395 $121–$1,211 $149
2023 $298,389 $443 $136–$1,283 $160
2024 $195,664 $450 $136–$1,323 $164
2025 $263,680 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. HeartFlow, Inc. $429,991 30 payments
  2. Neovasc Medical Inc $255,745 53 payments
  3. Ancora Heart, Inc. $243,513 17 payments
  4. Elucid $223,999 8 payments
  5. Impulse Dynamics (USA) Inc. $187,783 15 payments
  6. Shockwave Medical, Inc $180,000 20 payments
  7. Ablative Solutions, Inc. $168,040 11 payments
  8. Abbott Laboratories $119,074 49 payments
  9. W. L. Gore & Associates, Inc. $57,000 5 payments
  10. Abiomed $52,036 44 payments
  11. Other $74,721 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,798,988 158 payments
  2. Travel and Lodging $79,299 64 payments
  3. Honoraria $40,900 11 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,163 7 payments
  5. Grant $28,875 1 payment
  6. Food and Beverage $7,178 62 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $3,000 1 payment
  8. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,500 1 payment
Products named General payments · program years 2019–2025
  1. FFRct $297,191 22 payments
  2. PlaqueIQ $121,499 6 payments
  3. OPTIMIZER Cardiovascular Device $117,000 7 payments
  4. OPTIMIZER Cardiovascular Device $117,000 7 payments
  5. AccuCinch $108,371 6 payments
  6. Optimizer Cardiovascular $60,368 6 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $60,000 4 payments
  8. ElucidVivo $60,000 1 payment
  9. Optimizer Cardiovascular $59,954 5 payments
  10. Product in Development $57,000 5 payments
  11. Other $323,858 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ZOLL Circulation Inc $442,500 28 payments
  2. Abiomed $84 2 payments

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record